The story has been updated to include comments from Vermillion's conference call on Thursday.

NEW YORK (Genomeweb News) – Vermillion reported after the close of the market Thursday that its third quarter revenues were up 3 percent year over year at $330,000 versus $319,000 in Q3 2012.

The company posted product revenue of $216,000, up 5 percent from $205,000 year over year. That revenue was based on 4,328 OVA1 ovarian cancer tests performed in Q3 2013 versus 4,100 tests performed in the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.